Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells

about

Histone deacetylases in hearing loss: Current perspectives for therapy.

P2860

Q55475017-AF6C5318-2D74-451B-86F7-733AE6DF09E1

P2860

Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells

Item

http://www.wikidata.org/entity/Q42328146

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Histone Deacetylase Inhibitor ...... Agent for Larynx Cancer Cells

@en

Histone Deacetylase Inhibitor ...... Agent for Larynx Cancer Cells

@nl

type

Item

label

Histone Deacetylase Inhibitor ...... Agent for Larynx Cancer Cells

@en

Histone Deacetylase Inhibitor ...... Agent for Larynx Cancer Cells

@nl

prefLabel

Histone Deacetylase Inhibitor ...... Agent for Larynx Cancer Cells

@en

Histone Deacetylase Inhibitor ...... Agent for Larynx Cancer Cells

@nl

P1476

Histone Deacetylase Inhibitor ...... Agent for Larynx Cancer Cells

@en

P2093

Ewa Nowosadzka

http://www.w3.org/2001/XMLSchema#string

Ewelina Gumbarewicz

http://www.w3.org/2001/XMLSchema#string

Krystyna Kowalczuk

http://www.w3.org/2001/XMLSchema#string

Krzysztof Polberg

http://www.w3.org/2001/XMLSchema#string

Witold Jeleniewicz

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications

New and emerging HDAC inhibitors for cancer treatment

Histone deacetylases and cancer

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

Anticancer activities of histone deacetylase inhibitors

Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo

Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells.

Targeted inhibition of kinases in cancer therapy

The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells

P304

19-28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.16655

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andrzej Stepulak

Jarogniew J Luszczki

Magdalena Dmoszynska-Graniczka

Aneta Grabarska

K Kupisz

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28123594

http://www.w3.org/2001/XMLSchema#string

P921

Bagtingan

P932

5264036

http://www.w3.org/2001/XMLSchema#string

Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells

about

P2860

P2860

Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932